A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
Hutchmed
Children's National Research Institute
Vanquish Oncology, Inc.
Case Comprehensive Cancer Center
Grupo Espanol de Tumores Neuroendocrinos
Medical College of Wisconsin
Mateon Therapeutics
INSYS Therapeutics Inc
Novartis
National Institutes of Health Clinical Center (CC)